Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023.
作者信息
Gulati Shuchi, Lara Primo Nery
机构信息
Department of Internal Medicine, Division ofHematology and Oncology, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
出版信息
Kidney Cancer. 2024 Feb 8;8(1):23-24. doi: 10.3233/KCA-230024. eCollection 2024.
Abstract
摘要
相似文献
1
Belzutifan versus Everolimus in Advanced Kidney Cancer: A Commentary on LITESPARK-005 Trial from ESMO 2023.
Kidney Cancer. 2024 Feb 8;8(1):23-24. doi: 10.3233/KCA-230024. eCollection 2024.
2
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eur J Cancer. 2024 Jan;196:113434. doi: 10.1016/j.ejca.2023.113434. Epub 2023 Nov 15.
3
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Future Oncol. 2023 Dec;19(40):2631-2640. doi: 10.2217/fon-2023-0283. Epub 2023 Oct 26.
4
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy.
Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.
5
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Clin Cancer Res. 2024 May 1;30(9):1750-1757. doi: 10.1158/1078-0432.CCR-23-2592.
6
Belzutifan (Welireg) for advanced renal cell carcinoma.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e75-e76. doi: 10.58347/tml.2024.1701g.
7
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31.
8
.
Mol Pharmacol. 2022 Sep 27;102(6):MOLPHARM-AR-2022-000525. doi: 10.1124/molpharm.122.000525.
9
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
10
Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.
J Kidney Cancer VHL. 2022 Sep 28;9(3):41-46. doi: 10.15586/jkcvhl.v9i3.245. eCollection 2022.
引用本文的文献
1
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae369.
2
Management of Metastatic Renal Cell Carcinoma Following First-Line Immune Checkpoint Therapy Failure: A Systematic Review.
Cancers (Basel). 2024 Jul 20;16(14):2598. doi: 10.3390/cancers16142598.
3
mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process.
Int J Mol Sci. 2024 Jun 2;25(11):6141. doi: 10.3390/ijms25116141.
4
HIF2α inhibits glutaminase clustering in mitochondria to sustain growth of clear cell Renal Cell Carcinoma.
bioRxiv. 2025 Jan 7:2024.05.04.592520. doi: 10.1101/2024.05.04.592520.
本文引用的文献
1
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
2
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22.
3
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Lancet Oncol. 2020 Jan;21(1):95-104. doi: 10.1016/S1470-2045(19)30735-1. Epub 2019 Dec 3.
Zotero 插件